Reuters logo
in a month
BRIEF-FDA oncologic drugs advisory committee unanimously recommends approval of Mylan and Biocon's proposed biosimilar Trastuzumab
July 13, 2017 / 9:15 PM / in a month

BRIEF-FDA oncologic drugs advisory committee unanimously recommends approval of Mylan and Biocon's proposed biosimilar Trastuzumab

July 13 (Reuters) - Mylan Nv

* FDA oncologic drugs advisory committee unanimously recommends approval of Mylan and Biocon's proposed biosimilar Trastuzumab

* Mylan Nv - ‍Mylan and Biocon's proposed biosimilar trastuzumab also is under review by regulatory authorities in Australia, Canada, Europe

* U.S. FDA's committee voted 16-0 in support of eligible indications of the reference product, herceptin Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below